PTC Therapeutics, Inc. (PTCT) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

Earnings Reports

• PTC Therapeutics (PTCT) Q2 2026: Suffiance Drives 21% Sequential Growth, Global Launch Expands Revenue Base
  July 31, 2026
• PTC Therapeutics (PTCT) Q1 2026: Suffiance Drives 47% Product Revenue Growth, Recasts Global Rare Disease Trajectory
  May 08, 2026
• PTC Therapeutics (PTCT) Q4 2025: Suffiance Launch Drives 36% Product Revenue Growth Target
  February 23, 2026
• PTC Therapeutics (PTCT) Q3 2025: Suffiance Launch Adds $19.6M, Broad Uptake Signals Durable PKU Franchise
  November 05, 2025
• PTC Therapeutics (PTCT) Q2 2025: Suffiance Launch Targets $1B+ US Opportunity as DMD Franchise Holds 25% EU Revenue
  August 08, 2025
• PTC Therapeutics (PTCT) Q1 2025: $2B Cash Bolsters Multi-Asset Launch Cycle
  July 07, 2025

Browse all companies